Tumor Ablation Market

Tumor Ablation Market by Technology (Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Irreversible Electroporation (IRE), High-Intensity Focused Ultrasound (HIFU), and Others), Treatment Type (Surgical Ablation, Laparoscopic Ablation, and Percutaneous Ablation), Indication (Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Bone Metastasis, and Others), End-User (Hospitals & Clinics, Cancer Care Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cancer, increase in preference for minimally invasive procedures, increase in technological advancements in tumor ablation devices, and increasing strategic activities among the key players across the globe.

The global tumor ablation market was valued at USD 1,703.26 million in 2024, growing at a CAGR of 13.30% during the forecast period from 2025 to 2032 to reach USD 4,595.68 million by 2032. The rising prevalence of cancer globally drives the demand for effective treatments like tumor ablation. The growing preference for minimally invasive procedures stems from their shorter recovery times, lower risks, and cost-effectiveness compared to traditional surgical methods. Simultaneously, technological advancements in tumor ablation devices, including innovations in radiofrequency, microwave, and cryoablation technologies, have improved precision, safety, and efficacy, making these procedures more appealing to both patients and healthcare providers. Additionally, increasing strategic activities such as partnerships, mergers, and acquisitions among key market players enhance product availability and foster innovation, further fueling market expansion. Collectively, these factors are expected to strengthen the adoption and market penetration of tumor ablation therapies worldwide during the forecast period from 2025 to 2032.

Tumor Ablation Market Dynamics:

According to data provided by the World Cancer Research Fund (2024), in 2022, globally, there were more than 866,136 new cases of liver cancer.

According to recent data provided by GLOBOCAN (2024), in 2022, the estimated number of new cases of kidney cancer was 435,000 across the globe and the projections were estimated to increase by 693,000 by 2045.

Tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, are particularly effective for localized tumors in the liver and kidneys, where traditional surgical interventions may pose higher risks or are unsuitable due to patient comorbidities. Liver cancer, being one of the most commonly diagnosed cancers globally, drives the demand for ablation therapies as they are frequently used for patients with early-stage hepatocellular carcinoma (HCC) or those unsuitable for surgical resection. Similarly, kidney cancer cases, primarily renal cell carcinoma, have increased, boosting the adoption of tumor ablation as a nephron-sparing alternative, preserving kidney function while targeting malignant cells and thereby boosting the overall market of tumor ablation across the globe.

Furthermore, the rapid expansion of the strategic activities among the key market players of tumor ablation is significantly boosting the overall market, with several promising therapies advancing to Phase 3 clinical trials. For instance, in April 2023, Compal Electronics, a Taiwanese electronics company, launched a new radiofrequency ablation (RFA) system for percutaneous, intraoperative coagulation and ablation of soft tissue, including partial or complete ablation of non-resectable liver lesions.

Thus, the factors mentioned above are expected to boost the overall market of tumor ablation across the globe during the forecast period from 2025 to 2032.

However, the risk of complications such as bleeding, infection, damage to surrounding healthy tissues, or unintended injury to nearby organs and limited applicability for advanced cancers as tumor ablation techniques are most effective for localized, small-sized tumors. For advanced or metastatic cancers, these devices often cannot provide comprehensive treatment, necessitating combination therapies or alternative interventions which may result in slight obstacles to the growth of the tumor ablation market.

Tumor Ablation Market Segment Analysis:

Tumor Ablation Market by Technology (Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Irreversible Electroporation (IRE), High-Intensity Focused Ultrasound (HIFU), and Others), Treatment Type (Surgical Ablation, Laparoscopic Ablation, and Percutaneous Ablation), Indication (Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Bone Metastasis, and Others), End-User (Hospitals & Clinics, Cancer Care Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology type segment of the tumor ablation market, the microwave ablation segment is expected to hold a significant share in 2024.  Microwave Ablation (MWA) technology is significantly driving the growth of the tumor ablation market due to its numerous advantages over traditional ablation techniques and its expanding Indication in treating various cancers. MWA uses electromagnetic waves to generate heat, which effectively destroys cancerous cells by causing coagulative necrosis. One of the key factors boosting the market is its ability to treat larger tumors compared to radiofrequency ablation (RFA), as MWA achieves higher temperatures more quickly and penetrates deeper tissues with less risk of heat dissipation. This makes it particularly effective for treating liver, lung, kidney, and bone cancers, which are often challenging to manage with other methods.

The growing preference for minimally invasive procedures has further enhanced the adoption of MWA, as it offers reduced recovery time, minimal scarring, and fewer complications compared to traditional surgical approaches. Technological advancements, such as the development of precise, image-guided MWA systems, have improved targeting accuracy, ensuring better outcomes and reducing the risk of damage to surrounding healthy tissues. Moreover, MWA's compatibility with ultrasound, CT, or MRI guidance has made it a versatile choice in oncology treatment.

Furthermore, the increase in strategic activities among the key market players is further boosting the overall market of tumor ablation. For instance, in July 2024, Varian, a Siemens Healthineers company, announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system, which is intended for the ablation of soft tissue. The system was designed to offer clinicians improved predictability, precision, and control during procedures.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of tumor ablation across the globe.

North America is expected to dominate the overall tumor ablation market:

North America is expected to account for the highest proportion of the tumor ablation market in 2024, out of all regions. The region has a high prevalence of cancer, particularly liver, kidney, and lung cancers, which drives the demand for advanced treatment options like tumor ablation. Additionally, the strong presence of established healthcare infrastructure, coupled with the widespread adoption of minimally invasive procedures, supports the market's growth. Technological advancements in tumor ablation devices, such as microwave and radiofrequency systems, and favorable reimbursement policies further contribute to the dominance of North America. Moreover, significant investment in research and development and collaborations among leading market players enhance product innovation and accessibility, solidifying the region's leadership in this sector.

According to the recent data provided by GLOBOCAN (2024), in 2022, the estimated number of new cases of kidney cancer was 79800 and the projections were estimated to increase by 103,000 by 2045 in North America. Furthermore, the overall number of new cancer cases in North America in 2022 was 2.67 million and the projections were estimated to increase by 3.83 million by 2045. With a high prevalence of cancer cases such as liver, kidney, and lung, there is an escalating demand for effective, minimally invasive treatment options. Tumor ablation techniques, including radiofrequency and microwave ablation, offer targeted therapy with reduced recovery times, making them attractive alternatives to traditional surgical methods.

Minimally invasive tumor ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, typically involve smaller incisions compared to open surgery. This results in less pain, shorter hospital stays, and quicker recovery times for patients, which enhances their overall experience and satisfaction. Minimally invasive procedures can be performed on tumors located in challenging or hard-to-reach areas of the body. This makes them suitable for patients who may not be candidates for traditional surgery due to health conditions or the nature of their tumors.

Furthermore, the growing product approval of new tumor ablation further escalates the market for tumor ablation. For instance, in November 2022, Baird Medical received FDA approval for its microwave ablation device designed for treating thyroid nodules and other soft tissue conditions. This device enhances treatment options available to clinicians and reflects the industry's commitment to advancing minimally invasive techniques.

Thus, the above-mentioned factors are expected to escalate the market of tumor ablation in the region.

Tumor Ablation Market Key Players:

Some of the key market players operating in the tumor ablation market include Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc., Boston Scientific, Merit Medical Systems, Johnson & Johnson, Abbott., Olympus Corporation, Bioventus Inc., AngioDynamics, Mermaid Medical, HealthTronics, Inc., HealthTronics, Inc., AtriCure, Inc., Hologic, Inc., Smith & Nephew,  Hologic, Inc., and others.

Recent Developmental Activities in the Tumor Ablation Market:

• In March 2024, Medtronic received FDA clearance for OsteoCool™ 2.0 bone tumor ablation system.
• In September 2022, Stryker received FDA clearance for OptaBlate™ bone tumor ablation system.

Key Takeaways From the Tumor Ablation Market Report Study

• Market size analysis for current tumor ablation size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the tumor ablation market.
• Various opportunities available for the other competitors in the tumor ablation market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current tumor ablation market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for tumor ablation market growth in the coming future?

Target Audience Who Can be Benefited From This Tumor Ablation Market Report Study

• Tumor ablation product providers
• Research organizations and consulting companies
• Tumor ablation -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in tumor ablation
• Various end-users who want to know more about the tumor ablation market and the latest technological developments in the tumor ablation market. 

Frequently Asked Questions for the Tumor Ablation Market:

1. What is tumor ablation?

• Tumor ablation is a minimally invasive procedure that destroys cancerous tumors using techniques like heat, cold, or chemical agents, typically guided by imaging technologies such as ultrasound, CT, or MRI.

2. What is the market for tumor ablation?

• The global tumor ablation market was valued at USD 1,703.26 million in 2024, growing at a CAGR of 13.30% during the forecast period from 2025 to 2032 to reach USD 4,595.68 million by 2032.

3. What are the drivers for the global tumor ablation market?

• The rising prevalence of cancer globally drives the demand for effective treatments like tumor ablation. The growing preference for minimally invasive procedures stems from their shorter recovery times, lower risks, and cost-effectiveness compared to traditional surgical methods. Simultaneously, technological advancements in tumor ablation devices, including innovations in radiofrequency, microwave, and cryoablation technologies, have improved precision, safety, and efficacy, making these procedures more appealing to both patients and healthcare providers. Additionally, increasing strategic activities such as partnerships, mergers, and acquisitions among key market players enhance product availability and foster innovation, further fueling market expansion. Collectively, these factors are expected to strengthen the adoption and market penetration of tumor ablation therapies worldwide during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global tumor ablation market?

• Some of the key market players operating in the tumor ablation are Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc., Boston Scientific, Merit Medical Systems, Johnson & Johnson, Abbott., Olympus Corporation, Bioventus Inc., AngioDynamics, Mermaid Medical, HealthTronics, Inc., HealthTronics, Inc., AtriCure, Inc., Hologic, Inc., Smith & Nephew,  Hologic, Inc., and others.

5. Which region has the highest share in the global tumor ablation market?

• North America is expected to account for the highest proportion of the tumor ablation market in 2024, out of all regions. The region has a high prevalence of cancer, particularly liver, kidney, and lung cancers, which drives the demand for advanced treatment options like tumor ablation. Additionally, the strong presence of established healthcare infrastructure, coupled with the widespread adoption of minimally invasive procedures, supports the market's growth. Technological advancements in tumor ablation devices, such as microwave and radiofrequency systems, and favorable reimbursement policies further contribute to the dominance of North America. Moreover, significant investment in research and development and collaborations among leading market players enhance product innovation and accessibility, solidifying the region's leadership in this sector.